{"id":9318,"date":"2015-05-28T13:10:00","date_gmt":"2015-05-28T13:10:00","guid":{"rendered":"https:\/\/technopolis-group.com\/?post_type=report&p=9318"},"modified":"2020-02-26T14:36:36","modified_gmt":"2020-02-26T14:36:36","slug":"evaluative-study-on-the-cross-border-healthcare-directive","status":"publish","type":"report","link":"https:\/\/technopolis-group.com\/de\/report\/evaluative-study-on-the-cross-border-healthcare-directive\/","title":{"rendered":"Evaluative study on the Cross-Border Healthcare Directive"},"content":{"rendered":"\n

In 2011, the Cross-border Healthcare Directive introduced a general framework to clarify patients\u2019 rights with regard to accessing cross-border healthcare provision; guarantee the safety, quality and efficiency of care that they will receive in another EU Member State; and promote cooperation between Member States on healthcare matters. Member States had to pass their national laws implementing the Directive (transposition) until 25 October 2013. The European Commission is tasked to monitor that the transposition is implemented correctly in a timely fashion.<\/p>\n\n\n\n

Technopolis worked with partner organisations KPMG and empirica to evaluate the effectiveness of the implementation of the Directive for DG SANTE through desk research, a series of surveys and interviews with key stakeholders, including National Contact Points, healthcare providers, healthcare insures, patient organisations and national authorities across the EU, and pseudo-patient investigation. The study covered all 28 Member States with in-depth assessment of 12 focus countries to sample different structural, organisational and economic features with respect to their healthcare system.<\/p>\n\n\n\n

The study design focussed on specific evaluation questions grouped according to the following main areas:<\/p>\n\n\n\n